{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:01:32Z","timestamp":1785272492645,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.farma.2026.04.017","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:43:52Z","timestamp":1785271432000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Cost-effectiveness of immune checkpoint inhibitors for non-small cell lung cancer in a third level hospital"],"prefix":"10.1016","author":[{"given":"Ana","family":"\u00c1lvarez-Yuste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"P\u00e9rez-Ab\u00e1nades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Colomer-Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cuadrado-Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Rogado-Revuelta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Gallego-Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Aranguren-Oyarz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.04.017_bb0005","author":"Cancer today"},{"key":"10.1016\/j.farma.2026.04.017_bb0010","author":"Informe SEOM: Las cifras del C\u00e1ncer en Espa\u00f1a 2025"},{"key":"10.1016\/j.farma.2026.04.017_bb0015","author":"Organizaci\u00f3n Mundial de la Salud. Datos y cifras sobre el c\u00e1ncer"},{"key":"10.1016\/j.farma.2026.04.017_bb0020","author":"Grupo Espa\u00f1ol de C\u00e1ncer de Pulm\u00f3n"},{"key":"10.1016\/j.farma.2026.04.017_bb0025","author":"NCCN guidelines non-small cell lung cancer v 12.2025"},{"key":"10.1016\/j.farma.2026.04.017_bb0030","series-title":"Global Oncology Trends 2024: outlook to 2028","first-page":"71","author":"IQVIA Institute for Human Data Science","year":"2024"},{"key":"10.1016\/j.farma.2026.04.017_bb0035","series-title":"Gu\u00eda de evaluaci\u00f3n econ\u00f3mica de medicamentos","author":"Ministerio de Sanidad","year":"2024"},{"issue":"1","key":"10.1016\/j.farma.2026.04.017_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.farma.2026.04.017_bb0045","article-title":"New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.farma.2026.04.017_bb0050","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11096-018-0772-z","article-title":"A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice","volume":"41","author":"Merino Almaz\u00e1n","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"10.1016\/j.farma.2026.04.017_bb0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/ph15040489","article-title":"Effectiveness and cost-effectiveness profile of second-line treatments with Nivolumab, Pembrolizumab and Atezolizumab in patients with advanced non-small cell lung cancer","volume":"15","author":"Franchi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.farma.2026.04.017_bb0060","first-page":"23","article-title":"Costs and cost drivers associated with non-small-cell lung cancer patients who received two or more lines of therapy in Europe","volume":"12","author":"Verleger","year":"2020","journal-title":"Clin Outcomes Res CEOR"},{"issue":"9","key":"10.1016\/j.farma.2026.04.017_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CEOR.S121093","article-title":"Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer","volume":"30","author":"Isla","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.farma.2026.04.017_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report\u2013Part I","volume":"13","author":"Hay","year":"2010","journal-title":"Value Health"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:43:53Z","timestamp":1785271433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"alternative-id":["S1130634326001662"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.017","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Cost-effectiveness of immune checkpoint inhibitors for non-small cell lung cancer in a third level hospital","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}